Publication: Circulating and unique recombinant forms of HIV type 1 containing subsubtype A2
Issued Date
2006-07-01
Resource Type
ISSN
08892229
Other identifier(s)
2-s2.0-33745951215
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
AIDS Research and Human Retroviruses. Vol.22, No.7 (2006), 695-702
Suggested Citation
Unchalee Visawapoka, Sodsai Tovanabutra, Jeffrey R. Currier, Josephine H. Cox, Carl J. Mason, Monique Wasunna, Mathurose Ponglikitmongkol, William E. Dowling, Merlin L. Robb, Deborah L. Birx, Francine E. McCutchan Circulating and unique recombinant forms of HIV type 1 containing subsubtype A2. AIDS Research and Human Retroviruses. Vol.22, No.7 (2006), 695-702. doi:10.1089/aid.2006.22.695 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/23321
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Circulating and unique recombinant forms of HIV type 1 containing subsubtype A2
Other Contributor(s)
Abstract
HIV-1 strains containing sabsubtype A2 are relatively rare in the pandemic but have been repeatedly identified in Kenya, where candidate vaccines based in part on subtype A, but not A2 strains, may be evaluated. Among the most recent is CRF16_A2D, a circulating recombinant form (CMF) whose prototypes are complete or partial IUV-I sequences from Kenya, Korea, and Argentina. Using samples from blood bank discards in Kenya and complete genome sequencing, this report further documents CRF16_A2D and related recombinants and identifies a second CRF, CRF21_A2D. The two A2-containing CRFs, and two recombinants related to CRF16_A2D, share common structural elements bat appear to have been independently derived. Concerted selection may have influenced the emergence and spread of certain A2-containing strains in Kenya. The second complete subtype C sequence from Kenya is also reported here. Monitoring of A2-containing recombinants and subtype C strains, both relatively rare in Kenya, may be informative in the course of cohort development and evaluation of candidate vaccines. © Mary Ann Liebert, Inc.